Novartis Reports Positive Phase III Data for Remibrutinib in Chronic Inducible Urticaria

Nov 12, 2026, 1:06 PM ETTrialRead the original at marketscreener.com

Good for NVS

Novartis reported sustained benefit from remibrutinib in a 52-week study for chronic inducible hives. The drug is still under development, so approval and sales are not established.

NVS · Novartis

AI read · Good for NVS

The AI's read

The results give Novartis a stronger case for adding another treatment to its medicine lineup. The study describes lasting benefit, but the drug is still being studied. The report does not establish approval or sales.

Get alerts for NVS

Follow Novartis (NVS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NVS

Free on the App Store and Google Play, or on the web.